Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics is a promising clinical-stage biotechnology company with a diverse pipeline that includes CYWC628, CYPS317, CYMS101, and CybroCell for various chronic diseases with high unmet medical needs, such as diabetic foot ulcers, multiple sclerosis, psoriasis, and degenerative disc disease. The upcoming proof-of-concept interim clinical results for CYWC628 in diabetic foot ulcer patients are expected to be the key factor that will drive appreciation for the potential of the broader fibroblast therapy pipeline. The company's deep IP moat, versatile platform across indications, and scalability potential make it a strong candidate for success in the biotech space.

Bears say

FibroBiologics is facing a number of challenges in the biotech industry, including regaining compliance with Nasdaq's listing requirements, a recent dilutive public offering, and the need for validation of their fibroblast therapy in patients with diabetic foot ulcers (DFU) in the first half of 2026. With a conservative estimate of 8% market penetration and the potential for complications in their stem cell-based therapy, the future success of FibroBiologics remains uncertain, leading to a negative outlook on the company's stock. Further financial data indicates that their burn care program is a potential growth opportunity, but with a highly competitive market and challenges in achieving regulatory approval for their novel delivery system, it may not be enough to significantly impact their overall financials.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.